FILTER BY:
Details
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Address: 335 24th Ave N #200, Nashville, TN 37203, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: True
- Peritoneal: True
- Pericardial: True
- Tunica Vaginalis: True
Type: Epitheliod, Biphasic, Sarcomatoid
Condition: Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
Description: This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Research Center: SCRI Oncology Partners
Treatment Interventions: DRUG: ISM6331
Potential Impact: High
Clinical Trial Number: NCT06566079
Phase: Phase 1
Status: Recruiting
